More Evidence Linking ADT for Prostate Cancer to Adverse Neurocognitive Effects
Men treated with androgen deprivation therapy (ADT) for prostate cancer had a significantly higher risk of dementia and other neurocognitive disorders, according to a meta-analysis of more than 2.5 million patients. The magnitude of excess risk ranged from 20% for dementia to 66% for depression. The risk of Alzheimer’s disease, vascular dementia, and Parkinson’s disease […]
Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer
CHICAGO — Combining enzalutamide (Xtandi) with an androgen deprivation therapy (ADT) boosted metastasis-free survival (MFS) in patients with prostate cancer at high risk for biochemical recurrence, according to the EMBARK trial. After a median follow up of 60.7 months, the combination of enzalutamide and leuprolide acetate ADT demonstrated a 58% reduction in the risk of […]
Escalated ADT Falls Short in Men With High-Risk Features After Prostatectomy
SAN FRANCISCO — Add-on hormone therapy plus an antiandrogen to salvage radiation and androgen deprivation therapy (ADT) did not boost survival outcomes in high-risk prostate cancer. In the FORMULA-509 trial, the addition of 6 months of abiraterone acetate (Zytiga) and apalutamide (Erleada) to salvage radiation (RT) and 6 months of ADT with a GnRH agonist […]
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases
PARIS — In men undergoing radiotherapy after radical prostatectomy, 2 years of androgen deprivation therapy (ADT) improved outcomes when compared with a shorter course of ADT, according to results from the RADICALS-HD trial. At a median follow-up of more than 9 years, investigators found that the longer ADT duration improved metastasis-free survival (MFS) compared with […]
Rezvilutamide Bests Bicalutamide in Metastatic Prostate Cancer
In combination with androgen deprivation therapy (ADT), the novel androgen-receptor inhibitor rezvilutamide significantly improved radiographic progression-free survival (PFS) and overall survival (OS) compared with bicalutamide (Casodex) in patients with high-volume, metastatic, hormone-sensitive prostate cancer, the phase III CHART trial showed. Among 654 mostly Asian patients, median radiographic PFS was not reached in the rezvilutamide group […]
For Men on ADT, Checking Bone Density May Thwart Fractures
Bone density testing in older prostate cancer patients on androgen deprivation therapy (ADT) was significantly associated with a decreased risk for major osteoporotic fractures, but remains little used, a prospective population-based study found. In the cohort of nearly 55,000 men treated with ADT from 2005 to 2015, those who received dual x-ray absorptiometry (DXA) screening […]
Mixed Results With RT Plus Short-Term ADT in Intermediate-Risk Prostate Cancer
CHICAGO — Adding a short course of androgen deprivation therapy (ADT) to dose-escalated radiotherapy (RT) led to a mixed bag of outcomes in intermediate-risk prostate cancer, according to a large randomized trial. The addition of 6 months of ADT did not improve overall survival (OS) compared with RT alone, but the hormonal therapy was associated […]
Meta-Analysis Reaffirms Role of ADT With Radiotherapy in Prostate Cancer
CHICAGO — The use of androgen deprivation therapy (ADT) in conjunction with radiotherapy, as well as its prolonged use in the adjuvant setting, improved metastasis-free survival (MFS) and overall survival (OS) in patients with localized prostate cancer, a meta-analysis found. Adding ADT to radiotherapy significantly improved 12-year rates of MFS, the primary endpoint (HR 0.83, […]
ADT Options for Prostate Cancer Come Out Even for Heart Safety
Androgen deprivation therapy (ADT) options for prostate cancer seemed to have a similar impact on the risk of cardiovascular events among people with documented heart disease, according to results from the PRONOUNCE trial, although the study was terminated early due to slow accrual. In 545 men, there was no statistically significant difference in the rate […]
When Is ADT Right for Biochemically Recurrent Prostate Cancer?
Men with prostate cancer and biochemical recurrence (BCR) who delayed androgen deprivation therapy (ADT) still experienced long survival outcomes, researchers reported. In a retrospective study, men with a prostate-specific antigen doubling time (PSADT) of less than 10 months saw a median metastases-free survival (MFS) of 192 months when they delayed ADT until metastasis, and a […]